The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Ionova (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Sanofi (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Alkermes; Amcure; Amunix; Anaveon; Bristol-Myers Squibb; Janssen-Cilag; Nanobiotix; PharmaMar; PsiOxus Therapeutics; Roche/Genentech; Seagen; Servier; TargImmune Therapeutics
Research Funding - Achilles Therapeutics (Inst); BeiGene; START
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Sarina Anne Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Antoine Hollebecque
Honoraria - Amgen; Eisai; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Vladimir Galvao
Travel, Accommodations, Expenses - F. Hoffmann LaRoche
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Basilea; Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Fadi S. Braiteh
Honoraria - Amgen; ARIAD; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Daiichi Sankyo/Lilly; Genentech/Roche; Gilead Sciences; Guardant Health; Immunomedics; Incyte; Ipsen; Lexicon; Lilly; Puma Biotechnology; Regeneron; Sanofi/Aventis; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo/Lilly; Deciphera; Eisai; Exelixis; Genentech/Roche; Guardant Health; Immunomedics; Incyte; Ipsen; Lilly; Merck; Merck; Merck; Pfizer; Regeneron; Sanofi; Taiho Oncology; Taiho Oncology; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merck; Merrimack; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bayer/Onyx; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; HERON; Incyte; Insys Therapeutics; Ipsen; Lexicon; Merrimack; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Tesaro
 
Rachel E. Sanborn
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech/Roche; Janssen Oncology; Macrogenics
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - AstraZeneca
 
Peigen Zhou
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Travel, Accommodations, Expenses - Seagen
 
Natalya N. Nazarenko
Employment - Ipsen; Seagen
Stock and Other Ownership Interests - Seagen
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bayer; Bristol-Myers Squibb; G1 Therapeutics; Ipsen; Seagen; Takeda
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst)